Home · Health · Sep 4 archive
Novartis Cardiovascular Drug Fails Pivotal Study
Developing
In Short: Novartis announced its experimental cardiovascular drug failed a critical trial, dealing a significant setback to the company and related research efforts.
A closely watched experimental cardiovascular drug from Novartis has failed in a pivotal study, marking a major blow to the company's research and development efforts in this area.
The failure of the drug, which was aimed at targeting a common heart disease risk factor, comes as a significant disappointment to the pharmaceutical giant and researchers working on similar treatments.
What's confirmed
What's still developing
- Single-source account; further confirmation still arriving.
Sources
- STATlink